Novartis Nears $7B+ Acquisition of Avidity in RNA Therapeutics Push
Swiss pharmaceutical giant Novartis is reportedly in advanced discussions to acquire Avidity Biosciences in a deal that could value the RNA therapeutics company at over $7 billion. The potential acquisition represents Novartis’s latest strategic move to strengthen its position in next-generation gen